Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
International Society of Sports Nutrition Position Stand: Caffeine and Exercise Performance
Researchers who are studying the impact of GLP-1 agonists in addiction are hopeful
[24] [25] For patients with heart failure or chronic kidney disease, SGLT2 inhibitors are generally preferred, with GLP-1 agonists considered when SGLT2 inhibitors are not appropriate or for additional benefit
At present, there is limited direct research examining Wegovy and weed use together
[35] Drucker DJ
